Arvinas Shares Novel Oculomotor and Biomarker Data from Phase 1 Clinical Trial of ARV-102 in Patients with Parkinson’s Disease
Globe Newswire•07/10/2026•07:00 ET
0
Key Highlights
- ➤ARV-102 improved saccadic hypometria versus placebo after 28 days
- ➤ARV-102 reduced endolysosomal and neuroinflammatory biomarkers
- ➤ARV-102 increased synaptic integrity and axonal guidance biomarkers
- ➤LRRK2 CSF reductions correlated with oculomotor and pathway-biomarker changes
- ➤Phase 1 trial tested 20 mg to 80 mg doses in 24 Parkinson’s patients
Expert Statements
Ilaria Conti, Vice President, Clinical Research at Arvinas
“These final data from our Phase 1 study in patients with Parkinson’s disease provide further evidence that ARV-102 reaches the central nervous system, degrades LRRK2, and modulates biological pathways relevant to neurodegenerative disease.”
Ilaria Conti, Vice President, Clinical Research at Arvinas
“Although this study was not designed to assess clinical efficacy, we are encouraged by the exploratory dose-related changes in ocular saccadic hypometria and their associations with LRRK2 degradation and changes in pathway biomarkers.”
Ilaria Conti, Vice President, Clinical Research at Arvinas
“These findings support further clinical evaluation of ARV-102.”
– Data showed improvements in an objective measure of impaired eye movement associated with Parkinson’s disease, with a correlation between reductions in LRRK2 cerebrospinal fluid (CSF) biomarkers to these changes in oculomotor function and changes in synaptic biomarkers –
– Findings support continued evaluation of ARV-102 as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation –
Get started
Create a free account to read the full story.